Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 9,201–9,300 of 15,747
Advances in mRNA vaccines for viral diseases
Huang, Y., Zhu, X., Guo, X., Zhou, Y., Liu, D., Mao, J., Xiong, Y., Deng, Y., & Gao, X. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28924 · Cited by 5
The protective effect of previous COVID-19 infection in a high-prevalence hospital setting
Narrainen, F., Shakeshaft, M. K., Asad, H., Holborow, A., Blyth, I., & Healy, B. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0225 · Cited by 5
Conformational variability of loops in the SARS‐CoV ‐2 spike protein
Wong, S. W. K., & Liu, Z. (2021) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26266 · Cited by 4
Hayashi, M., Morikawa, S., Goto, Y., Yoshida, T., Kimura, Y., & Imaizumi, K. (2022) · PubMed Central · doi:10.20407/fmj.2021-009 · Cited by 4
“Past history Hypertension (15), Hyperlipidemia (7), Endometriosis (4), Diabetes (4), Dysmenorrhea (3), Hyperthyroidism (3), Ovarian cyst (2), Depression (2), Glaucoma (2), Epilepsy (1), SLE (1), Prostatic hypertrophy (1), RA (1), Dystonia (1), OSA (1), Migraine (1), Crohn’s disease (1), GERD (1), Cholelithiasis (1)”
Steroid injections in pain management: influence on coronavirus disease 2019 vaccines
Hong, S. M., Park, Y. W., & Choi, E. J. (2021) · The Korean journal of pain · doi:10.3344/kjp.2022.35.1.14 · Cited by 5
“For example, if a vaccine is shown to have an efficacy of 70%, it means that 70% of people who get this vaccine are less likely to contract the disease than those who get a placebo [6,7].”
BackgroundSystemic Emergencies in COVID-19 Patient: A Pictorial Review
Albanesi, M., Cozzi, D., Cavigli, E., Moroni, C., Frezzetti, G., Bartolini, L., & Miele, V. (2022) · Tomography · doi:10.3390/tomography8020084 · Cited by 5
“After months of research and collaboration between several nations, vaccines have been developed and have allowed a reduction in the incidence of infection and a lower occurrence of complications in previously vaccinated infected subjects [12,13].”
BackgroundFortunati, S., Giannetto, M., Giliberti, C., Bolchi, A., Ferrari, D., Locatelli, M., Bianchi, V., Boni, A., Munari, I. D., & Careri, M. (2022) · Sensors · doi:10.3390/s22145463 · Cited by 6
“Exceptional research efforts led to the rapid development of several vaccines which have already been distributed to a large part of the general population [5].”
BackgroundKim, B., & Kim, E. Y. (2023) · Vaccines · doi:10.3390/vaccines11030512 · Cited by 5
Yang, Z., Feng, T., Guan, W., He, J., Jiang, R., Liu, G., Lu, G., Lu, Q., Shen, A., Sun, L., et al. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-21-1613 · Cited by 4
“Phase III data for BNT162b2 by Pfizer/BioNTech reported that two BNT162b2 doses could reach 95% effectiveness in preventing infections in individuals ≥16 years (33), whereas for 12–15 years old, the effective prevention rate could reach 100% and was well tolerated (34).”
BackgroundViralFP: A Web Application of Viral Fusion Proteins
Moreira, P., Sequeira, A. M., Pereira, S., Rodrigues, R., Rocha, M., & Lousa, D. (2021) · Frontiers in Medical Technology · doi:10.3389/fmedt.2021.722392 · Cited by 6
“This group of vaccines include the Moderna’s mRNA-1273 (18) and the Pfizer-BioNTech’s BNT162b2 mRNA (19).”
BackgroundCho, O., Cho, Y.-H., & Chung, M.-Y. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910348 · Cited by 7
“Most of the current studies related to COVID‐19 have focused on epidemiology [20], the clinical course of the disease [21], the development and efficacy of vaccines [22], and infection control guidelines [23].”
BackgroundThe relationship between the immunogenicity and reactogenicity of vaccines: A narrative review
Gromer, D. J., Kalash, S., Tanios, R., & Rouphael, N. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127892 · Cited by 5
Xie, K., Zhu, L., Duan, M., Fu, Y. W., Wang, H., Shen, Y., Li, Y., Wang, R., Jiang, Z., Chen, S., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2519823123 · Cited by 9
Torres, I., Albert, E., Giménez, E., et al. (2021) · medRxiv · doi:10.1101/2021.04.19.21255723 · Cited by 5
Smit, W. L., Thijsen, S. F. T., van der Kieft, R., van Tol, S., Reimerink, J. H. J., Reusken, C. B. E. M., Rümke, L. W., Bossink, A. W. J., Limonard, G. J. M., & Heron, M. (2022) · Pathogens and Disease · doi:10.1093/femspd/ftac035 · Cited by 5
The Trade-off Between Prioritization and Vaccination Speed Depends on Mitigation Measures
Agarwal, N., Komo, A., Patel, C., Pathak, P. A., & Ünver, M. U. (2021) · National Bureau of Economic Research · doi:10.3386/w28519 · Cited by 8
Li, C., Jiang, C., Chao, T., Lin, S.-Y., Tsai, Y., Chao, C., Su, Y., Chen, C., Chang, S., Lin, F., et al. (2023) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-023-12490-8 · Cited by 7
“Based on the results from the clinical trials, the short-term efficacy of COVID-19 vaccines developed by Pfizer-BioNTech (BNT162b2 mRNA), Moderna (mRNA1273), and Johnson & Johnson (Jansen Ad26) against the ancestral SARS-CoV-2 strain and Alpha variant appeared to be comparable between individuals with obesity and thos…”
ResultEvolution of SARS-CoV-2 Spikes shapes their binding affinities to animal ACE2 orthologs
Yao, W., Li, Y., Ma, D., Hou, X.-D., Wang, H., Tang, X., Cheng, D., Zhang, H., Du, C., Pan, H., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02676-23 · Cited by 6
Optimizing the targeting of lipid nanoparticles for gene therapy
Yue, L., Gao, X., Qi, W., Zhang, L., & Wang, Y. (2026) · Nanoscale Horizons · doi:10.1039/d5nh00351b · Cited by 8
Muodiaju, J. C., & Madu, C. S. (2025) · Cureus · doi:10.7759/cureus.84821 · Cited by 8
“…cross-reactive T-cell epitopes that could serve as universal vaccine targets, reducing the severity of future outbreaks [12-15]. mRNA vaccines, such as those developed by Pfizer-BioNTech (New York, USA) and Moderna (Massachusetts, USA), have demonstrated high efficacy in preventing COVID-19 [16].”
Tacke, F., Cornberg, M., Sterneck, M. R., Trebicka, J., Settmacher, U., Bechstein, W. O., Berg, T., Deutsche Gesellschaft für Gastroenterologie, V. U. S. (., Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV), V. D. W. B., Deutsche Transplantationsgesellschaft (DTG), V. D. U. S., et al. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1372-5595 · Cited by 6
Bennett, J. C., Luiten, K. G., O’Hanlon, J., Han, P. D., McDonald, D., Wright, T., Wolf, C. R., Lo, N. K., Acker, Z., Regelbrugge, L., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.01.080 · Cited by 5
Diallo, A., Carlos‐Bolumbu, M., Diallo, M., Makinson, A., & Galtier, F. (2022) · Journal of Public Health · doi:10.1007/s10389-022-01707-1 · Cited by 6
IgA vasculitis presenting as nephrotic syndrome following COVID-19 vaccination: a case report
Cho, I., Kim, J.-K., & Kim, S. G. (2022) · BMC Nephrology · doi:10.1186/s12882-022-03028-7 · Cited by 5
Margenov, S., Popivanov, N. I., Ugrinova, I., & Hristov, T. (2023) · Mathematics · doi:10.3390/math11102238 · Cited by 7
The SARS-CoV-2 spike (S) and the orthoreovirus p15 cause neuronal and glial fusion
(2021) · doi:10.1101/2021.09.01.458544 · Cited by 94
Mencoboni, M., Fontana, V., Damiani, A., Spitaleri, A., Raso, A., Bottaro, L. C., Rossi, G., Canobbio, L., Camera, A. L., Filiberti, R. A., et al. (2022) · Current Oncology · doi:10.3390/curroncol29050273 · Cited by 5
Manjappa, S., Phi, H. Q., Lee, L. W., Onstad, L., Gill, D. B., Connelly‐Smith, L. S., Krakow, E. F., Flowers, M. E. D., Carpenter, P. A., Hill, J. A., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.08.026 · Cited by 6
“The seroconversion rate was higher after the initial series in our study compared with that in patients with hematologic malignancies as reported in other studies [5,6], although the seroconversion rate and titers were lower compared with those in healthy adults [1,2,18].”
A multi-layer model for the early detection of COVID-19
Shmueli, E., Mansuri, R., Porcilan, M., Amir, T., Yosha, L., Yechezkel, M., Patalon, T., Handelman-Gotlib, S., Gazit, S., & Yamin, D. (2021) · Journal of The Royal Society Interface · doi:10.1098/rsif.2021.0284 · Cited by 5
“These include the emergence of highly transmissible mutant strains [2,3], the non-optimal efficacy of the developed vaccines and the current disapproval of their administration to certain populations [4], the limited supply and distribution capacities of the vaccines [5], as well as the potential risk of vaccine-wanin…”
BackgroundAutoVEM2: A flexible automated tool to analyze candidate key mutations and epidemic trends for virus
Xi, B., Chen, Z., Li, S., Liu, W. Y., Jiang, D., Bai, Y., Qu, Y., Lon, J. R., Huang, L., & Du, H. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.002 · Cited by 6
“At present, a variety of vaccines against SARS-CoV-2 are being used over the world, including mRNA-1273 [2], BNT162b2 [3], CoronaVac [4] and so on, hoping to form the effect of herd immunity.”
How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?
Pons, S., Uhel, F., Frapy, E., Sérémé, Y., Zafrani, L., Aschard, H., & Skurnik, D. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10477-y · Cited by 6
“The success of the vaccines based on a new mRNA based approach are very promising [13, 145].”
BackgroundCourville, K., Bustamante, N., Núñez-Samudio, V., Pecchio, M., Landires, I., Viggiano, C., Durán, H., Novoa, N., Alvarado, E., Vargas, F., et al. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03529-w · Cited by 5
Taddio, A., McGilton, K. S., Zheng, N., Yeung, L., Lafleur, B., Fung, J. S. T., MacDonald, N. E., Andrew, M. K., & Verschoor, C. P. (2022) · Canadian Journal of Pain · doi:10.1080/24740527.2022.2115880 · Cited by 6
COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review
Shear, S. L., Shams, K., Weisberg, J., Hamidi, N., & Scott, S. C. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.03.006 · Cited by 6
“The COVID-19 vaccine randomised controlled trials noted systemic side-effects to be more frequent following the second dose [7,12,13].”
InfluentialMiocardite Aguda após a Vacina de mRNA contra a COVID-19
Gomes, D., Santos, R. R., Freitas, P., et al. (2022) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210469 · Cited by 5
Ma, J., Luo, J., & Xu, M. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-3064 · Cited by 4
“Briefly, vaccination plays a crucial role in diminishing the route of transmission (9,10).”
BackgroundCOVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis
Deodhar, A. A., Bhana, S., Winthrop, K. L., & Gensler, L. S. (2022) · Rheumatology and Therapy · doi:10.1007/s40744-022-00462-9 · Cited by 8
“Following a single dose of either vaccine, patients who experienced a prior SARS-CoV-2 infection and those who received two doses of the BNT162b2 vaccine achieved higher seroconversion rates.”
InfluentialPérinet, S., Cadieux, G., Mercure, S.-A., Drouin, M., & Allard, R. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.47042 · Cited by 5
Duque, J. S. R., Cheng, S. M. S., Cohen, C. A., Leung, D., Wang, X., Mu, X., Chung, Y., Lau, T. M., Wang, M., Zhang, W., et al. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-023-00764-0 · Cited by 5
“These findings were consistent with the observation that the efficacy of CoronaVac against infection appeared lower than that of BNT162b2 in separate pivotal clinical trials [6–8].”
No current evidence for risk of vaccine-driven virulence evolution in SARS-CoV-2
Miller, I. F., & Metcalf, C. J. (2020) · medRxiv · doi:10.1101/2020.12.01.20241836 · Cited by 5
RNA-based drugs: current, imminent and possible therapeutic applications
Torrisi, S. A., Geraci, F., Diolosà, L., Luca, A. D., Falzone, L., Drago, F., Libra, M., & Leggio, G. M. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108958 · Cited by 11
SARS-CoV-2 Viral Replication in a High Throughput Human Primary Epithelial Airway Organ ModelPreprint
Fisher, C. R., Medie, F. M., Luu, R. J., Gaibler, R. B., Miller, C. R., Mulhern, T. J., Vijayakumar, V., Marr, E. E., Alladina, J. W., Medoff, B. D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.15.448611 · Cited by 4
van der Weg, W., von Kreijfelt, G., Davidson, L., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127549 · Cited by 5
Frodlund, M., Nived, P., Chatzidionysiou, K., Södergren, A., Klingberg, E., Hansson, M., Ohlsson, S., Pin, E., Bengtsson, A. A., Klareskog, L., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.02981-23 · Cited by 7
“Three COVID-19 vaccines were introduced in Sweden in early 2021, i.e., two mRNA vaccine platforms (BNT162b2 and mRNA-1273), and one adenovirus vector vaccine (ChAdOx1 nCoV-19) (13–15).”
BackgroundGlobal control of COVID-19: good vaccines may not suffice
Eslava-Schmalbach, J., Rosero, E. B., & Orjuela, N. G. (2021) · Revista Panamericana de Salud Pública · doi:10.26633/rpsp.2021.148 · Cited by 8
Kjeldsen, S., Nielsen, J., Nørgård, B. M., & Kjeldsen, J. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab299 · Cited by 5
Walory, J., Książek, I., Karyński, M., & Baraniak, A. (2023) · Vaccines · doi:10.3390/vaccines11101578 · Cited by 5
Viral RNA blocks circularization to evade host codon usage control
Liu, H., Duan, J., Garg, R., Xie, P., & Liu, Y. (2025) · Nature · doi:10.1038/s41586-025-09809-y · Cited by 10
“On the flip side, codon usage optimization forms the basis of effective RNA-and DNA-based COVID-19 vaccines, which rely on translating viral protein-encoding RNA like cellular mRNAs 25,26 .”
Clinical Characteristics of COVID-19 Patients' Postvaccination
Zhang, X., Yang, S.-J., Lin, Y., Chen, L.-L., Zhuang, Y., & Zeng, H. (2022) · Viral Immunology · doi:10.1089/vim.2021.0204 · Cited by 6
“The efficacy of all vaccines is *70%; the mRNA vaccines have even up to 95% protective rate against COVID-19 (1,2,8).”
BackgroundPCR-generated DNA templates enable efficient, rapid, and cost-effective mRNA synthesis
Kumar, N., Hazell, N. C., Bei, J., Nguyen, T. K., & Hu, H. (2025) · Methods · doi:10.1016/j.ymeth.2025.08.007 · Cited by 5
Golec, M., Zembala-John, J., Fronczek, M., Konka, A., Bochenek, A., Wystyrk, K., Botor, H., Zalewska−Ziob, M., Chrapiec, M., Kasperczyk, S., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287128 · Cited by 8
Ashenagar, M. S., Matsumoto, A., Sakai, H., Tokiya, M., Hara, M., & Hirota, Y. (2022) · Vaccines · doi:10.3390/vaccines10040487 · Cited by 6
“Our observation indicates that anti-S protein S1 IgG levels significantly increased seven days after the first dose of the BNT162b2 vaccine, which is consistent with a previous report where the onset of protection was observed less than 14 days after the first vaccination in participants without evidence of prior infe…”
ResultDescribing mRNA Vaccine Technology for a Military Audience
Biggs, A. T., & Littlejohn, L. F. (2022) · Military Medicine · doi:10.1093/milmed/usac129 · Cited by 5
Vitamin D: A Nutraceutical Supplement at the Crossroad Between Respiratory Infections and COVID-19
Rizzi, M., & Sainaghi, P. P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062550 · Cited by 7
“Although the initial clinical trials resulted in a high level of effectiveness of these vaccines [13,162–166], variations in responsiveness between recipients emerged from real-world data [160,167], thus fostering research focused on the understanding of the factors affecting vaccine efficacy, in…”
Tokumasu, K., Fujita-Yamashita, M., Sunada, N., Sakurada, Y., Yamamoto, K., Nakano, Y., Matsuda, Y., Otsuka, Y., Hasegawa, T., Hagiya, H., et al. (2023) · Vaccines · doi:10.3390/vaccines11111661 · Cited by 8
Jozani, K. A., Shen, K., Anvari, N., Hocevar, D., Jiang, R., Zhang, B., Yakavets, I., & Zhao, Y. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115835 · Cited by 8
PARAMETER ESTIMATION OF COVID-19 COMPARTMENT MODEL IN INDONESIA USING PARTICLE SWARM OPTIMIZATION
Musafir, R. R., & Anam, S. (2022) · Jurnal Berkala Epidemiologi · doi:10.20473/jbe.v10i32022.283-292 · Cited by 6
Ozaki, M., Kuwayama, T., Shimotsuma, M., & Hirose, T. (2024) · Analytical Methods · doi:10.1039/d4ay00114a · Cited by 5
Determinants of COVID-19 vaccine hesitancy among pregnant persons
Ramonfaur, D., Hinojosa-Gonzalez, D. E., Rodríguez, R. G., et al. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.05.002 · Cited by 5
Novel Coronavirus: A Review from Origin to Current Status of Therapeutic Strategies
Hassan, M., Zalkifal, M., Wahab, A., Afzal, S., Rafique, S., Shahid, M., Khan, M. A., Ahmed, N., Idrees, M., & Shahıd, A. A. (2021) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2021038075 · Cited by 7
Elumalai, K., Srinivasan, S., & Anandakumar, S. (2024) · Gastroenterology & Endoscopy · doi:10.1016/j.gande.2024.01.003 · Cited by 6
Græsbøll, K., Eriksen, R. S., Kirkeby, C., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00621-9 · Cited by 5
Namageyo-Funa, A., Ruffin, J. D., Killerby, M. E., Jalloh, M. F., Scott, C., Lindell, K., Silver, M., Matanock, A. M., Soto, R. A., Donnelly, M. A. P., et al. (2022) · AJPM Focus · doi:10.1016/j.focus.2022.100004 · Cited by 5
The value of vaccine programme impact monitoring during the COVID-19 pandemic
Ortiz, J. R., & Neuzil, K. M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02322-9 · Cited by 7
Statewide evaluation of COVID-19 vaccine hesitancy in Rhode Island
Rogers, B. G., Tao, J., Almonte, A. A., Toma, E., Nagel, K., Fain, R., Napoleon, S. C., Maynard, M. A., Murphy, M., Sarkar, I. N., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268587 · Cited by 6
“Vaccines against COVID-19 have demonstrated significant efficacy in disease prevention and are likely to yield great benefit if implemented effectively at the population level [4, 5].”
BackgroundKhullar, N., Bhatti, J. S., Singh, S., Thukral, B., Reddy, P. H., & Bhatti, G. K. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i14.2064 · Cited by 6
Corowa-kun: Impact of a COVID-19 vaccine information chatbot on vaccine hesitancy, Japan 2021Preprint
Kobayashi, T., Nishina, Y., Tomoi, H., Harada, K., Tanaka, K., Matsumoto, E., Horimukai, K., Ishihara, J., Sasaki, S., Inaba, K., et al. (2021) · medRxiv · doi:10.1101/2021.05.26.21257854 · Cited by 4
Immune imprinting and antibody profiles to SARS-CoV-2 in urban and rural Ghana
Montiel-Ruiz, M., Lomotey, E. S., Obeng-Aboagye, E., Quaye, I. K., Odumang, D. A., Amakye, F. B., Logonia, B. A., Lochmann, S., Hayford, J. A., Osabutey, D., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112511 · Cited by 5
Goda, Y., Nakajima, D., Tanaka, S., Yamada, Y., Yutaka, Y., Unagami, K., Yoshikawa, M., Egawa, H., & Date, H. (2022) · General Thoracic and Cardiovascular Surgery · doi:10.1007/s11748-022-01887-3 · Cited by 6
Seegers, V., Rousseau, G., Zhou, K., Blanc-Lapierre, A., Bigot, F., Mahammedi, H., Lambert, A., Moreau-Bachelard, C., Campone, M., Conroy, T., et al. (2023) · Cancers · doi:10.3390/cancers15194777 · Cited by 5
“Most vaccine failures were observed early, either between the two doses [15] or soon after the second dose [17], but in these preliminary reports the median follow-up was short (2–3 months).”
BackgroundIkuse, T., Aizawa, Y., Shobukawa, Y., Tomiyama, N., Nakayama, H., Takahashi, M., Muto, K., Hasegawa, S., Takahashi, M., Kon, M., et al. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003607 · Cited by 5
Galanis, P., Vraka, I. S., Siskou, O. C., Konstantakopoulou, O., Katsiroumpa, A., Moisoglou, I., & Καϊτελίδου, Δ. (2021) · medRxiv · doi:10.1101/2021.09.30.21264344 · Cited by 5
“From early 2021, the ability to vaccinate against the COVID-19 with safe and effective vaccines is the best hope to control the pandemic (Baden et al., 2021; Haas et al., 2021; Polack et al., 2020).”
BackgroundMateo‐Urdiales, A., Fabiani, M., Mayer, F., Sacco, C., Belleudi, V., Cas, R. D., Fotakis, E. A., Angelis, L. D., Cutillo, M., Petrone, D., et al. (2024) · BMC Public Health · doi:10.1186/s12889-024-19071-y · Cited by 4
“The efficacy of these vaccines was demonstrated in experimental studies [2–6], and several observational studies have corroborated their effectiveness post-authorisation [7–9].”
BackgroundLuo, L., Chen, Q., Han, X., Shen, M., Hu, C., Chen, S., Zhang, J., Wang, Y., Li, T., Huang, J., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696662 · Cited by 5
Risk for Facial Palsy after COVID-19 Vaccination, South Korea, 2021–2022
Yoon, D., Jung, K., Kim, J. H., Ko, H. Y., Yoon, B., Shin, J., & CoVaSC Investigators (2024) · Emerging infectious diseases · doi:10.3201/eid3011.240610 · Cited by 6
He, Z., Le, Z., Shi, Y., Liu, L., Liu, Z., & Chen, Y. (2023) · Angewandte Chemie · doi:10.1002/ange.202310401 · Cited by 6
Giles, M., Krishnaswamy, S., Coote, W., & Davey, M. (2023) · Vaccines · doi:10.3390/vaccines11111713 · Cited by 5
Ribeiro, T. B., Roque, F., Ida, F., Plácido, A. I., Vu, M., Hernández‐Muñoz, J. J., & Herdeiro, M. T. (2022) · Vaccines · doi:10.3390/vaccines10111896 · Cited by 6
Suzuki, Y., Shibata, Y., Minemura, H., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2118653/v1 · Cited by 5
Hepatitis B reactivation: A possible cause of coronavirus disease 2019 vaccine induced hepatitis
Wu, H.-Y., Su, T., Liu, C., Yang, H., Tsai, J., Wei, M., Chen, C., Tung, C., Kao, J., & Chen, P. (2023) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2023.06.007 · Cited by 6
Tinnitus and COVID-19: effect of infection, vaccination, and the pandemic
Tai, Y., Jain, N., Kim, G., & Husain, F. T. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1508607 · Cited by 7
“As such, even though many studies have attempted to unfold the association between tinnitus and COVID-19, the knowledge gap could still be enlarged due to inconsistent reporting, recall bias, or the nocebo effect (52, 65).”
Luis, T. J. (2022) · Archives of Family Medicine and General Practice · doi:10.36959/577/505 · Cited by 5
Takotsubo Cardiomyopathy and COVID-19: A Case Report and Literature Review
Carrizales‐Sepúlveda, E. F., Flores‐Ramírez, R., Solís, J. G., et al. (2022) · Current Cardiology Reviews · doi:10.2174/1573403x18666220818155039 · Cited by 5
“The impact this protection could have in reducing cases of TTS related to COVID-19 remains to be studied [61].”
BackgroundMcGonagle, D., & Giryes, S. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103642 · Cited by 7
Hirsch, O., & Rinner, C. (2023) · doi:10.32920/24595017.v1 · Cited by 3
Cruz, P., Lam, J. M., Abdalla, J., Bell, S., Bytyci, J., Brosh‐Nissimov, T., Gill, J. S., Haidar, G., Hoerger, M. P., Maor, ., et al. (2024) · Vaccines · doi:10.3390/vaccines13010019 · Cited by 8
“…rates, that need a long time to be ascertained and are likely affected by healthcare system capacity in addition to strain virulence, like in the first clinical trials of SARS-CoV-2 vaccines [18,19]. addition to strain virulence, like in the first clinical trials of SARS-CoV-2 vaccines [18,19].”
Coronavirus (COVID-19) vaccines
Blekić, M., & Bukvić, B. K. (2021) · Liječnički vjesnik · doi:10.26800/lv-143-5-6-7 · Cited by 5
Osibogun, A. O., Shuaib, F. M., Adeyeye, C. M., Onajole, A. T., Ejembi, C. L., Banwat, M., Wright, O., Mohammed, A., Adeleye, O. A., Yahya, S., et al. (2023) · Nigerian Postgraduate Medical Journal · doi:10.4103/npmj.npmj_299_22 · Cited by 6
Montalti, M., Guaraldi, F., Valerio, Z. D., Ragghianti, B., Tedesco, D., Mannucci, E., Monami, M., & Gori, D. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2106747 · Cited by 6
“Incidence of fever, fatigue, headache, muscle and joint pain was in line with the general population immunized with Comirnaty®, with the exception of less frequent diarrhea.(28)”
ResultSukik, L., Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf098 · Cited by 6
“…for understanding the impact of the virus and its variants on public health [2–4], guiding the implementation of public health measures [5, 6], informing the development of vaccines and treatments [7–9], and evaluating the effectiveness of vaccines, treatments, and other interventions [10, 11].”
Janžič, U., Bidovec‐Stojkovič, U., Mohorčič, K., Mrak, L., Dovnik, N. F., Ivanović, M., Ravnik, M., Čakš, M., Škof, E., Debeljak, J., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0148 · Cited by 5
Should Antipyretics Be Used to Relieve Acute Adverse Events Related to COVID-19 Vaccines?
Etminan, M., Sodhi, M., & Ganjizadeh‐Zavareh, S. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.01.080 · Cited by 6
Global research on RNA vaccines for COVID-19 from 2019 to 2023: a bibliometric analysis
Chen, Z., Liu, Z., Feng, Y., Shi, A., Wu, L., Sang, Y., & Li, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1259788 · Cited by 8
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.